Radioiodine refractory differentiated thyroid cancer

Area of Science:

• Oncology
• Endocrinology
• Nuclear Medicine

Background:

• Differentiated thyroid cancer (papillary, follicular) is typically treated with thyroxine suppression and radioiodine ablation.
• A small percentage of patients experience recurrence or metastases, necessitating reoperation and further radioiodine treatment.

Purpose of the Study:

• To define criteria for radioiodine refractoriness in differentiated thyroid cancer patients.
• To highlight the challenges in managing patients resistant to standard radioiodine therapy.

Main Methods:

• Review of clinical criteria for defining radioiodine refractoriness.
• Analysis of patient outcomes based on radioiodine uptake and disease progression.

Main Results:

• Radioiodine refractoriness is characterized by negative or partial radioiodine uptake (RAI), or disease progression post-treatment.
• Progression after significant radioiodine cumulative doses (e.g., >600mCi) also indicates refractoriness.

Conclusions:

• Clear criteria are essential for identifying differentiated thyroid cancer patients refractory to radioiodine.
• Management of radioiodine-refractory thyroid cancer requires consideration of alternative therapeutic approaches.